Citadel Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-233,876
| Closed | -$234K | – | 6907 |
|
|
2022
Q4 | $234K | Buy |
233,876
+41,723
| +22% | +$41.7K | ﹤0.01% | 4549 |
|
|
2022
Q3 | $346K | Sell |
192,153
-165,069
| -46% | -$297K | ﹤0.01% | 4420 |
|
|
2022
Q2 | $1.04M | Buy |
357,222
+39,438
| +12% | +$114K | ﹤0.01% | 3366 |
|
|
2022
Q1 | $877K | Sell |
317,784
-196,717
| -38% | -$543K | ﹤0.01% | 3872 |
|
|
2021
Q4 | $2.4M | Buy |
514,501
+139,492
| +37% | +$650K | ﹤0.01% | 2852 |
|
|
2021
Q3 | $3.19M | Sell |
375,009
-4,987
| -1% | -$42.4K | ﹤0.01% | 2491 |
|
|
2021
Q2 | $6.24M | Sell |
379,996
-209,555
| -36% | -$3.44M | ﹤0.01% | 1905 |
|
|
2021
Q1 | $13M | Sell |
589,551
-495,417
| -46% | -$10.9M | ﹤0.01% | 1240 |
|
|
2020
Q4 | $33.6M | Buy |
1,084,968
+1,059,386
| +4,141% | +$32.8M | 0.01% | 604 |
|
|
2020
Q3 | $520K | Buy |
+25,582
| New | +$520K | ﹤0.01% | 3466 |
|
|
2020
Q2 | – | Sell |
-17,077
| Closed | -$132K | – | 5480 |
|
|
2020
Q1 | $132K | Buy |
+17,077
| New | +$132K | ﹤0.01% | 4243 |
|